Does Cigna Cover Zepbound? The 2026 Coverage Rules, Copay Ranges, and Prior Authorization Requirements

Key Takeaways

• Cigna covers Zepbound on most of its commercial pharmacy plans, but coverage is not automatic. Prior authorization (PA) is required.
• The standard Cigna PA criteria for Zepbound require a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbid condition.
• Zepbound is typically a Tier 3 specialty medication on Cigna formularies, with copays ranging from $50 to $250 per month after deductible.
• Cigna's Express Scripts pharmacy benefit manager handles most Zepbound claims and applies the same PA criteria across most employer-sponsored plans.
• Self-funded employer plans can opt out of Zepbound coverage entirely. Coverage is plan-specific, not Cigna-wide.

Direct answer (40-60 words)

Cigna covers Zepbound on most commercial pharmacy plans, but only with prior authorization. Standard PA criteria require a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity. Copays typically run $50 to $250 monthly after deductible. Self-funded employer plans can exclude Zepbound, so coverage is plan-specific.

Table of contents

1. The 30-second answer
2. How to check if your specific Cigna plan covers Zepbound
3. The standard Cigna prior authorization criteria
4. Cigna's formulary tiers and what they mean for Zepbound copay
5. Self-funded vs fully-insured plans (why coverage varies)
6. The Cigna PA process step by step
7. Common reasons Cigna denies Zepbound prior authorization
8. How to appeal a Cigna Zepbound denial
9. What to do if Cigna won't cover it
10. Cost comparison: covered Zepbound vs cash vs compounded alternative
11. FAQ
12. Sources
13. Footer disclaimers

How to check if your specific Cigna plan covers Zepbound

Cigna isn't one plan. The name covers commercial group health plans, individual marketplace plans, Medicare Advantage plans, and the Express Scripts pharmacy benefit manager that processes most Cigna prescription claims. Coverage rules differ across these.

The fastest way to confirm coverage for your specific plan:

Step 1. Log into your myCigna account.

Step 2. Navigate to "Pharmacy" then "Find a Drug" or "Drug Pricing."

Step 3. Search "Zepbound" and your dosage. The portal will return your formulary tier, copay estimate, and any restrictions (PA required, quantity limits, step therapy).

Step 4. If the portal flags PA, click through to see the specific criteria your plan uses.

Step 5. Call Cigna member services at the number on your card to confirm the portal information matches the most current plan documents. Plan terms can change at renewal even mid-year for some self-funded employers.

If your portal says Zepbound isn't covered or shows it as "excluded," your specific plan has chosen not to cover anti-obesity medications. This is a plan-level decision, not a Cigna-wide policy.

The standard Cigna prior authorization criteria

Cigna and Express Scripts publish standard PA criteria for Zepbound that most plans inherit. The criteria as of Q1 2026 are:

Required elements:

• Adult patient (18 or older)
• Documented BMI of 30 kg/m² or higher (obesity), or BMI of 27 kg/m² or higher with at least one weight-related comorbid condition
• Comorbid conditions accepted: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, established cardiovascular disease, polycystic ovary syndrome, non-alcoholic steatohepatitis, or osteoarthritis affecting weight-bearing joints
• Documentation of a reduced-calorie diet and increased physical activity attempted for at least 6 months before starting Zepbound
• Prescription written by a provider familiar with anti-obesity treatment

Common quantity limit:

• 4 pens per 28-day supply (1 pen per week)

Common step therapy requirement:

• Some plans require trial of phentermine or another older anti-obesity medication first. Some require step-through Wegovy or Saxenda. Others have no step therapy.

Reauthorization requirements:

• After initial 6 months, plans typically require documented weight loss of 5% or more from baseline to continue coverage. The 5% threshold is the FDA's clinical efficacy benchmark for anti-obesity medications.
• Reauthorization usually runs 12 months at a time after the initial 6-month review.

Documentation your provider will need to submit:

• Recent (within 6 months) weight, height, and BMI
• ICD-10 codes for obesity (E66.x) and any comorbidities
• Medical record entries documenting the 6 months of lifestyle changes
• For comorbid PA pathway: lab values or diagnostic codes confirming the comorbidity

These criteria are guidance. Individual employer plans can negotiate looser or stricter requirements. Marketplace plans and Cigna's own individual products generally follow the standard criteria.

Cigna's formulary tiers and what they mean for Zepbound copay

Cigna's commercial formularies use a 4 to 5 tier structure. Zepbound's tier placement determines your copay or coinsurance.

Tier	Description	Typical Zepbound placement	Typical patient cost
Tier 1	Preferred generics	Not applicable	$5 to $15
Tier 2	Preferred brand	Rare for Zepbound	$30 to $75
Tier 3	Non-preferred brand or specialty	Most common for Zepbound	$75 to $250
Tier 4	Specialty	Some plans	20% to 40% coinsurance
Tier 5	Excluded	Some self-funded employer plans	Full cash price

For most Cigna commercial members, expect Zepbound to land on Tier 3, which corresponds to a copay in the $75 to $200 range per month after the deductible is met.

Before the deductible is met, you typically pay the negotiated rate Cigna and the pharmacy have agreed to. For Zepbound this is usually $850 to $1,000 per month, similar to other commercial insurer negotiated rates.

The Eli Lilly Zepbound savings card can reduce eligible copays to as little as $25 per month for commercially insured patients. The card has a per-fill cap (currently around $150 in benefit per fill) and a 24-month maximum use period.

Self-funded vs fully-insured plans (why coverage varies)

The largest factor determining your specific Cigna Zepbound coverage isn't Cigna; it's whether your employer's plan is self-funded or fully-insured.

Fully-insured plans: the employer pays Cigna a premium, and Cigna takes on the financial risk for claims. These plans use Cigna's standard formulary by default and tend to have predictable coverage rules.

Self-funded plans: the employer pays claims out of its own funds and uses Cigna only to administer the plan. Self-funded employers have wide latitude to customize their formulary, including:

• Excluding Zepbound entirely
• Requiring stricter PA criteria (e.g., higher BMI threshold)
• Requiring step therapy through Wegovy or older medications first
• Capping the duration of coverage

Self-funded plans are most common at large employers (500+ employees). Roughly 65% of U.S. workers with employer health insurance are on self-funded plans, per the 2024 KFF Employer Health Benefits Survey.

If you work at a company that excludes anti-obesity medications, no amount of provider advocacy will get Cigna to cover Zepbound for you. The exclusion is the employer's choice. The remedy is asking your HR/benefits team about the exclusion at open enrollment, or pursuing Zepbound coverage through a spouse's plan if available.

The Cigna PA process step by step

The PA process is your provider's responsibility, but understanding the timeline helps you set expectations.

Day 0: Provider writes the Zepbound prescription. Pharmacy attempts to fill, returns "PA required" reject message.

Day 1 to 3: Provider's office submits PA paperwork to Cigna or Express Scripts. Submission methods include CoverMyMeds, ePA through the EHR, fax, or the Cigna provider portal.

Day 3 to 14: Cigna or Express Scripts reviews the PA. Standard review timeline is 72 hours for non-urgent requests, 24 hours for urgent. Real-world timing is often slower because of incomplete documentation.

Day 14 to 21: Decision returned. If approved, the pharmacy can fill on the next attempt. If denied, the denial letter explains the reason.

Day 21 to 60+ (if denied): Appeal process. The provider submits additional documentation or a peer-to-peer review request. Cigna has 30 days to respond to a first-level appeal, 30 more days for a second-level appeal.

The fastest path through PA is making sure the provider's submission is complete the first time. The most common reasons for PA delays are missing height/weight, missing comorbidity documentation, or missing 6-month lifestyle attempt notes.

Common reasons Cigna denies Zepbound prior authorization

Based on industry-wide data on GLP-1 PA denials and Cigna's own published criteria, the most common denial reasons:

1. BMI below threshold. If your BMI is 26.9 instead of 27, the PA fails on documentation. Sometimes this resolves with weight verification at the next visit if your weight has fluctuated.

2. Missing or insufficient comorbidity documentation. "Patient has high blood pressure" in a chart note doesn't always satisfy Cigna's criteria. Specific BP readings, ICD-10 codes, and prescribed antihypertensive medications strengthen the file.

3. No documented 6-month lifestyle program. Cigna often requires evidence that diet and exercise were attempted for 6 months before pharmacotherapy. Provider notes that say "patient has been trying to lose weight" don't satisfy this. Specific diet program names, dietitian visits, exercise logs, or weight-management program enrollment do.

4. Step therapy not completed. If your plan requires trying Wegovy or phentermine first, going straight to Zepbound triggers denial.

5. Off-label indication. Zepbound is FDA-approved for chronic weight management in patients with obesity. Prescribing for other indications (diabetes management is Mounjaro's indication, not Zepbound's) commonly triggers denial.

6. Prescriber type concern. Some plans flag PAs from providers who aren't endocrinologists or obesity-medicine specialists. Most Cigna plans don't have this restriction, but it's worth checking your specific plan documents.

7. Lapse in reauthorization documentation. At the 6-month mark, if weight loss wasn't documented or wasn't 5% or more, reauthorization can fail.

The denial letter should specify which criterion wasn't met. That tells the provider what to add for an appeal.

How to appeal a Cigna Zepbound denial

Cigna's commercial plans offer a multi-level appeal process.

First-level appeal. The provider or patient writes to Cigna explaining why the denial should be overturned. Submit any missing documentation, additional clinical justification, and references to the FDA-approved indication. Cigna has 30 days to respond.

Peer-to-peer review. The prescriber requests a phone consultation with a Cigna medical reviewer. The two providers discuss the clinical case directly. This often resolves marginal denials quickly because it bypasses the documentation review process.

Second-level appeal. If the first-level appeal fails, a second appeal is sent to a different Cigna reviewer. Patient advocacy here is helpful. A letter from the patient describing impact and quality-of-life issues sometimes shifts the decision.

External review. If both internal appeals fail, ERISA and state insurance laws give patients a right to external review by an independent review organization. The external reviewer's decision is binding on Cigna for fully-insured plans.

Appeal success rates vary, but published industry data suggests roughly 30 to 40% of GLP-1 prior authorization denials are overturned on first or second appeal when the patient and provider follow through. Many denials happen because of incomplete documentation rather than substantive ineligibility, so adding missing pieces frequently flips the decision.

What to do if Cigna won't cover it

If you've exhausted appeals or your plan excludes Zepbound entirely, options remain.

Eli Lilly Zepbound savings card. Available to commercially insured patients. Reduces eligible copay to as little as $25 per month. Doesn't help if your plan excludes Zepbound entirely (the card reduces copays; it doesn't replace coverage).

Eli Lilly direct-to-consumer pricing. As of 2024 to 2026, Eli Lilly began offering Zepbound vial-and-syringe formulations at reduced direct-to-consumer pricing through LillyDirect. The price varies by dose ($349 to $549 per month at the time of writing), substantially less than retail pen pricing.

Patient assistance program. Eli Lilly's PAP provides Zepbound free or low-cost to patients meeting income eligibility (typically below 400% of federal poverty level) without insurance coverage. Application requires provider involvement.

Compounded tirzepatide. State-licensed 503A compounding pharmacies prepared compounded tirzepatide during the Zepbound shortage. With FDA's 2024 to 2025 guidance on compounded GLP-1s, this option has narrowed but still exists in some markets, generally at $199 to $499 per month through telehealth platforms. Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound.

Switch to a different GLP-1. Wegovy (semaglutide) is sometimes covered when Zepbound isn't, depending on your plan's formulary. Saxenda (liraglutide) is older and sometimes the required step-therapy drug.

Re-evaluate at open enrollment. If your current plan excludes anti-obesity drugs, switching to a plan that covers them at next open enrollment is the cleanest fix.

Cost comparison: covered Zepbound vs cash vs compounded alternative

A quick comparison of monthly cost across pathways for a typical patient.

Pathway	Monthly cost	Conditions
Cigna covered + savings card	$25 to $50	Approved PA, commercial insurance, savings card eligible
Cigna covered, no savings card	$75 to $250	Approved PA, after deductible met
Cigna covered, deductible not met	$850 to $1,000	Negotiated rate applies until deductible met
Zepbound cash price (no insurance)	$1,060 to $1,200	Retail pharmacy cash price
LillyDirect vial pricing	$349 to $549	Direct from manufacturer, vial-and-syringe form
Patient Assistance Program	$0	Income below 400% FPL, no other coverage
Compounded tirzepatide via telehealth	$199 to $499	Not FDA-approved, not interchangeable

The total annual difference between "Cigna covered with savings card" ($300 to $600 per year) and "no insurance, no programs" ($12,720 to $14,400) is the difference between affordable and prohibitive. Working through the PA process is worth the effort for most patients.

FAQ

Does Cigna cover Zepbound for weight loss? Most Cigna commercial plans cover Zepbound for weight loss with prior authorization. Standard criteria require BMI 30 or higher, or 27 or higher with a weight-related comorbidity. Self-funded employer plans can exclude Zepbound entirely, so coverage depends on your specific plan.

How much does Zepbound cost with Cigna insurance? After deductible is met, expect a copay of $75 to $250 per month for Zepbound on most Cigna plans. With the Eli Lilly Zepbound savings card, eligible patients can pay as little as $25 per month. Before deductible is met, you'll pay the negotiated rate of about $850 to $1,000.

Does Cigna require prior authorization for Zepbound? Yes. Almost every Cigna plan requires prior authorization for Zepbound. The standard PA criteria require BMI documentation, comorbidity documentation if applicable, evidence of a 6-month lifestyle intervention, and reauthorization at 6 months based on weight loss progress.

What BMI does Cigna require for Zepbound coverage? Cigna's standard PA criteria require a BMI of 30 or higher. Patients with a BMI of 27 or higher can also qualify if they have at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, etc.).

How long does Cigna take to approve Zepbound prior authorization? Standard PA review is 72 hours for non-urgent requests after Cigna receives complete documentation. Real-world timing often runs 7 to 14 days because of incomplete initial submissions or back-and-forth on documentation. Urgent requests are reviewed in 24 hours.

What happens if Cigna denies my Zepbound PA? You can appeal. First-level appeals get a 30-day response from Cigna. Peer-to-peer reviews between your prescriber and Cigna's medical reviewer often resolve denials quickly. If internal appeals fail, external review by an independent review organization is available under ERISA and state insurance laws.

Will Cigna cover Zepbound for diabetes? Zepbound is FDA-approved for chronic weight management, not diabetes. The same molecule (tirzepatide) for diabetes is sold as Mounjaro. Cigna typically directs diabetes patients to Mounjaro through its formulary rather than approving Zepbound off-label.

Does Cigna Medicare Advantage cover Zepbound? Medicare doesn't cover anti-obesity medications under Part D rules. Zepbound is excluded from Medicare coverage for weight loss. Cigna Medicare Advantage plans follow this rule. Some Cigna Medicare Advantage plans cover Mounjaro (the same molecule) for diabetes patients.

What if my employer's Cigna plan excludes Zepbound? Self-funded employer plans can exclude anti-obesity medications. If your plan excludes Zepbound, your options are LillyDirect, the Eli Lilly Patient Assistance Program, switching to a covered alternative like Wegovy or Saxenda, or pursuing coverage through a spouse's plan.

Does Cigna require step therapy for Zepbound? Some Cigna plans require trial of Wegovy, phentermine, or another anti-obesity medication before approving Zepbound. Step therapy requirements vary by plan. Check your specific plan's PA criteria for step-therapy language.

How do I appeal a Cigna Zepbound denial? Have your provider submit a first-level appeal with complete documentation. If denied, request a peer-to-peer review with Cigna's medical reviewer. If still denied, file a second-level appeal. If both internal appeals fail, request external review by an independent review organization.

Can I use the Eli Lilly Zepbound savings card with Cigna? Yes, if you have commercial Cigna insurance and meet the savings card eligibility (not on Medicare/Medicaid/TRICARE/VA). Bring both your insurance card and the savings card to the pharmacy. The pharmacist runs your insurance first, then applies the savings card to reduce your copay.

Sources

1. Cigna 2026 Standard Prescription Drug List (Formulary), accessed Q1 2026.
2. Express Scripts Prior Authorization Criteria for GLP-1 Receptor Agonists for Weight Management, 2025 to 2026 update.
3. Eli Lilly Zepbound Prescribing Information, revised 2024.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
5. KFF Employer Health Benefits Survey 2024 (self-funded vs fully-insured plan distribution).
6. Eli Lilly LillyDirect Direct-to-Consumer Pricing Pages, 2025 to 2026.
7. Eli Lilly Patient Assistance Program Eligibility Documentation, 2026.
8. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Drugs Guidance, 2025.
9. ERISA External Review Process Regulations, 29 CFR 2590.715-2719.
10. American Medical Association. Prior Authorization Practice Resources, 2024 to 2025.
11. National Comprehensive Cancer Network and AHA Joint Statement on Obesity Management, 2023 (cited for comorbidity criteria).

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Cigna and Express Scripts are registered trademarks of The Cigna Group. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.